BR112015025398A2 - inibidores de metástase - Google Patents
inibidores de metástaseInfo
- Publication number
- BR112015025398A2 BR112015025398A2 BR112015025398A BR112015025398A BR112015025398A2 BR 112015025398 A2 BR112015025398 A2 BR 112015025398A2 BR 112015025398 A BR112015025398 A BR 112015025398A BR 112015025398 A BR112015025398 A BR 112015025398A BR 112015025398 A2 BR112015025398 A2 BR 112015025398A2
- Authority
- BR
- Brazil
- Prior art keywords
- metastasis inhibitors
- methods
- inhibiting
- cancer
- metastasis
- Prior art date
Links
- 239000002257 antimetastatic agent Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361808966P | 2013-04-05 | 2013-04-05 | |
| PCT/US2014/033206 WO2014165853A1 (en) | 2013-04-05 | 2014-04-07 | Inhibitors of metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015025398A2 true BR112015025398A2 (pt) | 2017-10-10 |
Family
ID=51654619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015025398A BR112015025398A2 (pt) | 2013-04-05 | 2014-04-07 | inibidores de metástase |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9408886B2 (https=) |
| EP (1) | EP2981279B1 (https=) |
| JP (1) | JP6449849B2 (https=) |
| KR (1) | KR102191695B1 (https=) |
| CN (1) | CN105517562B (https=) |
| AU (1) | AU2014247979B2 (https=) |
| BR (1) | BR112015025398A2 (https=) |
| CA (1) | CA2908832C (https=) |
| DK (1) | DK2981279T3 (https=) |
| ES (1) | ES2714863T3 (https=) |
| HU (1) | HUE043971T2 (https=) |
| IL (1) | IL241937B (https=) |
| MX (1) | MX363077B (https=) |
| PL (1) | PL2981279T3 (https=) |
| PT (1) | PT2981279T (https=) |
| RU (1) | RU2681213C2 (https=) |
| SG (2) | SG10201708125PA (https=) |
| WO (1) | WO2014165853A1 (https=) |
| ZA (1) | ZA201508010B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201708125PA (en) | 2013-04-05 | 2017-11-29 | Biomarck Pharmaceuticals Ltd | Inhibitors of metastasis |
| CN108686220A (zh) * | 2018-07-13 | 2018-10-23 | 刘慧荣 | 一种针对甲状腺癌的抗肿瘤剂 |
| EP4475866A4 (en) * | 2022-02-07 | 2026-02-25 | Park Strategic Ventures Llc | Peptides and their methods of use in the treatment of eye disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501911B2 (en) | 1999-02-24 | 2013-08-06 | Biomarck Pharmaceuticals, Ltd | Methods of reducing inflammation and mucus hypersecretion |
| US7544772B2 (en) * | 2001-06-26 | 2009-06-09 | Biomarck Pharmaceuticals, Ltd. | Methods for regulating inflammatory mediators and peptides useful therein |
| US7265088B1 (en) | 2000-02-24 | 2007-09-04 | North Carolina State University | Method and compositions for altering mucus secretion |
| PT1411967E (pt) | 2001-06-26 | 2011-09-30 | Univ North Carolina State | Péptido bloqueador que atua sobre a secreção de células inflamatórias |
| JP2005523879A (ja) * | 2001-10-05 | 2005-08-11 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | Ｓｉｒｓ／ｓｅｐｓｉｓを治療及び予防するための組成物及び方法 |
| DE60308251T2 (de) | 2002-04-17 | 2007-08-30 | Canon K.K. | Vorrichtung zur Bereitstellung von öffentlichen Schlüsselzertifikaten |
| NZ577196A (en) | 2005-01-20 | 2011-06-30 | Biomarck Pharmaceuticals Ltd | Mucin hypersecretion inhibitors based on the structure of MANS and methods of use |
| WO2006086681A2 (en) * | 2005-02-09 | 2006-08-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of inhibiting smooth muscle cell migration and proliferation |
| CN103990111B (zh) | 2006-07-26 | 2016-08-31 | 拜欧马克医药有限公司 | 减少炎症介质释放的方法和可用于该方法的肽 |
| WO2008127355A2 (en) * | 2006-10-06 | 2008-10-23 | Celtaxsys, Inc. | Chemorepulsion of cells |
| KR20090086415A (ko) | 2006-10-27 | 2009-08-12 | 조지 매이슨 인털렉춸 프로퍼티즈, 인코퍼레이티드 | 전이성 결장직장 암에 대한 검정 |
| WO2009062128A2 (en) * | 2007-11-08 | 2009-05-14 | Indiana University Research And Technology Corporation | Combination drug therapy for the treatment of cancer |
| EP2105511A1 (en) * | 2008-03-28 | 2009-09-30 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung |
| US9073974B2 (en) * | 2009-12-21 | 2015-07-07 | The Regents Of The University Of California | RGD-containing cyclic peptides |
| EP3351641A1 (en) * | 2011-04-08 | 2018-07-25 | Tufts Medical Center, Inc. | Pepducin design and use |
| SG10201708125PA (en) | 2013-04-05 | 2017-11-29 | Biomarck Pharmaceuticals Ltd | Inhibitors of metastasis |
-
2014
- 2014-04-07 SG SG10201708125PA patent/SG10201708125PA/en unknown
- 2014-04-07 WO PCT/US2014/033206 patent/WO2014165853A1/en not_active Ceased
- 2014-04-07 CN CN201480031461.3A patent/CN105517562B/zh not_active Expired - Fee Related
- 2014-04-07 JP JP2016506681A patent/JP6449849B2/ja not_active Expired - Fee Related
- 2014-04-07 PT PT14779844T patent/PT2981279T/pt unknown
- 2014-04-07 US US14/246,864 patent/US9408886B2/en active Active - Reinstated
- 2014-04-07 PL PL14779844T patent/PL2981279T3/pl unknown
- 2014-04-07 EP EP14779844.1A patent/EP2981279B1/en active Active
- 2014-04-07 BR BR112015025398A patent/BR112015025398A2/pt not_active Application Discontinuation
- 2014-04-07 ES ES14779844T patent/ES2714863T3/es active Active
- 2014-04-07 KR KR1020157031658A patent/KR102191695B1/ko not_active Expired - Fee Related
- 2014-04-07 RU RU2015146997A patent/RU2681213C2/ru active
- 2014-04-07 SG SG11201508249WA patent/SG11201508249WA/en unknown
- 2014-04-07 CA CA2908832A patent/CA2908832C/en active Active
- 2014-04-07 DK DK14779844.1T patent/DK2981279T3/en active
- 2014-04-07 MX MX2015014036A patent/MX363077B/es unknown
- 2014-04-07 HU HUE14779844A patent/HUE043971T2/hu unknown
- 2014-04-07 AU AU2014247979A patent/AU2014247979B2/en not_active Ceased
-
2015
- 2015-10-06 IL IL241937A patent/IL241937B/en active IP Right Grant
- 2015-10-28 ZA ZA2015/08010A patent/ZA201508010B/en unknown
-
2016
- 2016-07-06 US US15/203,376 patent/US10011636B2/en active Active
-
2018
- 2018-06-04 US US15/996,797 patent/US10683328B2/en active Active - Reinstated
-
2020
- 2020-06-12 US US16/900,130 patent/US11466054B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018010089A2 (pt) | composições compreendendo cepas bacterianas | |
| MX369863B (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| BR112017023821A2 (pt) | moduladores de k-ras | |
| MX2019011905A (es) | Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica. | |
| BR112017005266A2 (pt) | inibidores de mk2 e uso dos mesmos | |
| MX376078B (es) | Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer. | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| UA117011C2 (uk) | Фармацевтичний склад омекамтиву мекарбілу і спосіб його застосування | |
| BR112015032062A2 (pt) | aduto de aceitador de michael contendo enxofre, composição, aduto de aceitador de michael contendo enxofre terminado por hidroxila e aduto contendo enxofre terminado por amina | |
| LT3371165T (lt) | Btk inhibitorius, naudojamas vėžiui gydyti | |
| PH12017500293A1 (en) | Boronic acid derivatives | |
| CL2016000326A1 (es) | Composiciones y método para tratar condiciones asociadas con el complemento | |
| MX2017004037A (es) | Derivados de acido boronico. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| MX2017004043A (es) | Derivados de acido boronico. | |
| MX2017001490A (es) | Combinaciones de farmacos para tratar mieloma multiple. | |
| MX370336B (es) | Derivados de acido boronico. | |
| EA201790189A1 (ru) | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе | |
| EA201590744A1 (ru) | Лечение рака tor киназными ингибиторами | |
| PT2968226T (pt) | Composições de oxprenolol para tratamento do cancro | |
| PT3016682T (pt) | Métodos para tratamento do cancro | |
| EP2994542A4 (en) | Compositions for ovarian cancer assessment having improved specificity | |
| BR112019004481A2 (pt) | aptâmeros específicos de pd-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |